Passage Bio, Inc. (PASG)

NASDAQ: PASG · IEX Real-Time Price · USD
1.02
+0.02 (1.57%)
At close: May 26, 2023, 4:00 PM
0.998
-0.020 (-1.75%)
After-hours: May 26, 2023, 6:22 PM EDT
1.57%
Market Cap 55.49M
Revenue (ttm) n/a
Net Income (ttm) -127.65M
Shares Out 54.63M
EPS (ttm) -2.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 40,053
Open 1.01
Previous Close 1.00
Day's Range 0.99 - 1.04
52-Week Range 0.95 - 2.89
Beta 0.99
Analysts Strong Buy
Price Target 8.80 (+766.4%)
Earnings Date May 11, 2023

About PASG

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the br... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 28, 2020
Employees 85
Stock Exchange NASDAQ
Ticker Symbol PASG
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for PASG stock is "Strong Buy." The 12-month stock price forecast is $8.8, which is an increase of 766.40% from the latest price.

Price Target
$8.8
(766.40% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights

PHILADELPHIA, May 11, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (C...

2 weeks ago - GlobeNewsWire

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, April 21, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system ...

1 month ago - GlobeNewsWire

Passage Bio to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system ...

1 month ago - GlobeNewsWire

Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

PHILADELPHIA, March 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system ...

2 months ago - GlobeNewsWire

Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights

PHILADELPHIA, March 06, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system ...

3 months ago - GlobeNewsWire

Passage Bio to Present at Cowen 43rd Annual Health Care Conference

PHILADELPHIA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

3 months ago - GlobeNewsWire

Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023

PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

3 months ago - GlobeNewsWire

Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023

PHILADELPHIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

3 months ago - GlobeNewsWire

Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023

– Updated interim data from first six patients in Phase 1/2 Imagine-1 study of PBGM01 for GM1 Gangliosidosis to be shared in oral platform and poster presentations

3 months ago - GlobeNewsWire

Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study

PHILADELPHIA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

5 months ago - GlobeNewsWire

Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates

PHILADELPHIA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

7 months ago - GlobeNewsWire

Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022

PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

7 months ago - GlobeNewsWire

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

8 months ago - GlobeNewsWire

Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer

PHILADELPHIA, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

8 months ago - GlobeNewsWire

Passage Bio to Present at Chardan's 6th Annual Genetic Medicines Conference

PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system ...

8 months ago - GlobeNewsWire

Newman Ferrara LLP Announces Corporate Governance Investigations of Passage Bio, Inc. (PASG)

NEW YORK--(BUSINESS WIRE)---- $PASG #NYTop100--Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Passage Bio, Inc. (NASDAQ: PASG) (“Passage” or...

9 months ago - Business Wire

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

PHILADELPHIA, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

10 months ago - GlobeNewsWire

Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations

PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

10 months ago - GlobeNewsWire

Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference

PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

10 months ago - GlobeNewsWire

Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights

PHILADELPHIA, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

10 months ago - GlobeNewsWire

Passage Bio to Report Second Quarter 2022 Financial Results on August 4, 2022

PHILADELPHIA, July 28, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

10 months ago - GlobeNewsWire

Passage Bio Appoints Michael Kamarck, Ph.D. to Board of Directors

PHILADELPHIA, July 06, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

11 months ago - GlobeNewsWire

Passage Bio to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

PHILADELPHIA, June 09, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system d...

1 year ago - GlobeNewsWire

Passage Bio Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy

• PBML04 represents the company's fourth program to receive IND clearance

1 year ago - GlobeNewsWire

Passage Bio Announces Leadership Transition

PHILADELPHIA, June 01, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

1 year ago - GlobeNewsWire